FDA Grants Accelerated Approval to Ultragenyx's GENGLYCOS, First-Ever Gene Therapy for GSDIa
On August 19, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Ultragenyx Pharmaceutical's GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, for the treatment of adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). GENGLYCOS represents the first-ever FDA-approved therapy designed to treat the underlying cause of GSDIa, a rare genetic metabolic disorder, and is Ultragenyx's first approved gene therapy.
Clinical Performance and Regulatory Commitments
The approval was supported by the 48-week randomized, double-blind, placebo-controlled Phase 3 GlucoGene study, which evaluated 46 participants aged eight years and older. Patients treated with GENGLYCOS demonstrated a statistically significant reduction in daily oral cornstarch requirements—the standard nutritional management used to prevent severe hypoglycemia—compared to the placebo group (p<0.001).
According to the official launch announcement:
"GENGLYCOS is the first FDA‑approved treatment designed to address the underlying cause of GSDIa and Ultragenyx’s first approved gene therapy, and it reduces daily cornstarch intake as an adjunct to nutritional management. Approval is based on the 48‑week randomized, double‑blind, placebo‑controlled Phase 3 GlucoGene study in 46 participants, in which DTX401 significantly reduced cornstarch requirements versus placebo (p<0.001)."
Because the drug received accelerated approval, Ultragenyx is required to verify its long-term clinical benefit through a post-marketing program:
"Continued approval may depend on verification of clinical benefit through a post‑marketing program including 2‑year data from 50 commercial patients and 20 controls and long‑term follow‑up via the GSDIa Disease Monitoring Program for up to 10 years."
Safety Profile and Treatment Constraints
GENGLYCOS carries significant safety warnings and contraindications:
- It is strictly contraindicated in patients with severe hepatic fibrosis or cirrhosis.
- Immune-mediated hepatotoxicity was reported, with ALT/AST elevations occurring in 71% of treated patients.
- Common adverse events (occurring in $\ge 10%$ of patients) include nausea (38%), adrenal insufficiency (24%), hypertriglyceridemia (29%), and anaphylaxis/infusion reactions (10%).
- The therapy carries a theoretical risk of tumorigenicity arising from AAV vector DNA integration.
Upon approval, the FDA also awarded Ultragenyx a Priority Review Voucher. The therapy will be manufactured at Ultragenyx’s Bedford, Massachusetts facility.